TY  - JOUR
U1  - Wissenschaftlicher Artikel
A1  - Ose, Jennifer
A1  - Gigic, Biljana
A1  - Brezina, Stefanie
A1  - Lin, Tengda
A1  - Baierl, Andreas
A1  - Geijsen, Anne J. M. R.
A1  - Roekel, Eline van
A1  - Robinot, Nivonirina
A1  - Gicquiau, Audrey
A1  - Achaintre, David
A1  - Keski-Rahkonen, Pekka
A1  - Duijnhoven, Fränzel J. B. van
A1  - Gumpenberger, Tanja
A1  - Holowatyj, Andreana N.
A1  - Kok, Dieuwertje E.
A1  - Koole, Annaleen
A1  - Schrotz-King, Petra
A1  - Ulrich, Alexis B.
A1  - Schneider, Martin
A1  - Ulvik, Arve
A1  - Ueland, Per-Magne
A1  - Weijenberg, Matty P.
A1  - Habermann, Nina
A1  - Scalbert, Augustin
A1  - Gsur, Andrea
A1  - Ulrich, Cornelia M.
T1  - Targeted Plasma Metabolic Profiles and Risk of Recurrence in Stage II and III Colorectal Cancer Patients: Results from an International Cohort Consortium
JF  - Metabolites
N2  - The identification of patients at high-risk for colorectal cancer (CRC) recurrence remains an unmet clinical need. The aim of this study was to investigate associations of metabolites with risk of recurrence in stage II/III CRC patients. A targeted metabolomics assay (128 metabolites measured) was performed on pre-surgery collected EDTA plasma samples from n = 440 newly diagnosed stage II/III CRC patients. Patients have been recruited from four prospective cohort studies as part of an international consortium: Metabolomic profiles throughout the continuum of CRC (MetaboCCC). Cox proportional hazard models were computed to investigate associations of metabolites with recurrence, adjusted for age, sex, tumor stage, tumor site, body mass index, and cohort; false discovery rate (FDR) was used to account for multiple testing. Sixty-nine patients (15%) had a recurrence after a median follow-up time of 20 months. We identified 13 metabolites that were nominally associated with a reduced risk of recurrence. None of the associations were statistically significant after controlling for multiple testing. Pathway topology analyses did not reveal statistically significant associations between recurrence and alterations in metabolic pathways (e.g., sphingolipid metabolism p = 0.04; pFDR = 1.00). To conclude, we did not observe statistically significant associations between metabolites and CRC recurrence using a well-established metabolomics assay. The observed results require follow-up in larger studies.
KW  - colorectal cancer
KW  - recurrence
KW  - targeted metabolomics
KW  - Dickdarmkrebs
KW  - Rezidiv
KW  - Metabolomik
Y1  - 2021
UN  - https://nbn-resolving.org/urn:nbn:de:bsz:960-opus4-30870
SN  - 2218-1989
SS  - 2218-1989
U6  - https://doi.org/10.25968/opus-3087
DO  - https://doi.org/10.25968/opus-3087
VL  - 11
IS  - 3
SP  - 14
S1  - 14
ER  -